Sun Pharmaceutical Industries, a leading Indian pharmaceutical company has started voluntary recall of multiple lots of Bupropion Hydrochloride Extended-release Tablets USP (SR), 200 mg, 60-count bottle, from the US market for failed dissolution specification. According to a USFDA notification, Sun Pharma's recall was initiated last month under Class-III classification which was as 'a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences'. Approximately 35,235 bottles (60 count) of Bupropion Hydrochloride extended-release tablets distributed by the company have been recalled.
Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world.
